Menu
Recruiting NCT04806295

The Leukemia and Lymphoma Society (LLS) National Research Registry

Observational Blood Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: any/all treatments for blood cancer.
Who it may be relevant to
Registry conditions: Blood Cancer. Basic parameters: from 21 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The Leukemia and Lymphoma Society (LLS) has built a National Research Registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.

Detailed description

The LLS National Research Registry is a real-world experiences and outcomes research registry; a collection of patient information and medical data, over time, about people who have a particular disease or condition, or who receive a particular treatment.

The LLS National Research Registry Protocol will:

1. Answer research questions using data collected from people with blood cancers. Such research involves analyses of subject profile information completed by subjects and medical records data. 2. Obtain permission from LLS National Research Registry research subjects to have Ciitizen, a third-party engaged by LLS, act as their proxy to retrieve full medical record data including images at no cost to research subjects. Note: Patient can choose to upload their medical records into their account, directly. 3. Obtain permission from LLS National Research Registry research subjects to share summary data with research partners (like academic researchers, advocacy groups, and pharmaceutical companies) that are advancing treatments for blood cancer. "Summary data" represents the important elements of medical record data, coded for research use, with personal identifiers like name, address, and phone number removed. 4. Obtain permission from LLS National Research Registry research subjects to be contacted from time to time, for them to provide updated medical information.

Interventions

  • Other any/all treatments for blood cancer
    Following people undergoing any/all treatments for blood cancer.

Primary outcome measures

  • LLS will monitor outcomes of people being treated for blood cancer. [Time frame: 10 years]

Eligibility criteria

Inclusion criteria

People with blood cancer, before, during, and after blood cancer treatments.

Exclusion criteria

People unable or unwilling to sign informed consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • Lymphoma and Leukemia Society — Rye Brook

Identifiers

NCT: NCT04806295 · LLSNRR-17-001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗